This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

CommitmentHeritageInitiativesInnovationPortfolio

Menu

Close

Information on adverse event reporting can be found at the bottom of this page.

Our Oncology Portfolio

At Pfizer, we apply science and our global resources to bring therapies to people that may extend or help to improve their lives.

 

Over the past decade, we’ve taken bold new approaches to translate scientific research into effective medicines for people living with cancer. Today, our portfolio includes cancer medicines and biosimilars across multiple indications, including breast, genitourinary, blood and lung cancers. 

Over 20

approved oncology medicines and biosimilars1

Button Loading
More than 30

therapeutic indications in different cancers1

Button Loading
Around 839,000

people around the world treated with Pfizer Oncology products in 20211

Button Loading
Our Oncology Brands
Learn moreLoading

Prescribing Information

Learn moreLoading

Prescribing Information

Learn moreLoading

Prescribing Information

Learn moreLoading

Prescribing Information

Learn moreLoading

Prescribing Information

 

In Northern Ireland, Lorviqua (lorlatinib) has a conditional marketing authorisation.

Learn moreLoading

Prescribing Information

Prescribing Information

Prescribing Information

Prescribing Information

Learn moreLoading

Prescribing Information

Prescribing Information

Learn moreLoading

Prescribing Information

Prescribing Information

Explore Pfizer Oncology 
Innovation in Oncology

We believe nothing is more urgent, or more personal, than our goal to develop the next generation of potential cancer therapies.

Find out moreLoading
Commitment to Oncology

We're proud to partner with organisations that share our purpose to deliver the right treatment for each patient, at the right time.

Find out moreLoading
Our Oncology Heritage

For over two decades, we have worked tirelessly in our pursuit to develop innovative and accessible treatments for those living with cancer. 

Find out moreLoading
Initiatives in Oncology

In addition to manufacturing medicines, we're engaged in a number of initiatives that we hope will improve the lives of those impacted by cancer.

Find out moreLoading

References:
1. Pfizer data on file. 

PP-UNP-GBR-7081. October 2023.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​